Rationale and Design of the DIPAK 1 Study: A Randomized Controlled Clinical Trial Assessing the Efficacy of Lanreotide to Halt Disease Progression in Autosomal Dominant Polycystic Kidney Disease

Author(s):
Meijer, E.; Drenth, J.P.H.; d'Agnolo, H.; Casteleijn, N.F.; Fijter, J.W. de; Gevers, T.J.; Kappert, P.; Peters, D.J.M. (0000-0001-6974-7143); Salih, M.; Soonawala, D.; Spithoven, E.M.; Torres, V.E.; Visser, F.W.; Wetzels, J.F.M.; Zietse, R.; Gansevoort, R.T.; DIPAK Consortium
Published
2014
Publication type
Article / Letter to editor
Polycystic kidney disease (PKD)cyst progressionglomerular filtration rate (GFR)kidney volumequality of life (QoL)disease trajectoryrenal diseasesomatostatin analog
Date issued
2014-03-31
Language
English
Is part of
American Journal of Kidney Diseases (2014), Vol. 63, no. 3, p. 446-455
hdl
1887/104707
doi
10.1053/j.ajkd.2013.10.011